Nasdaq Stockholm AB has approved Acarix AB (publ) as issuer of shares on Nasdaq First North Premier. First day of trading will commence on December 19, 2016.

Press Release December 16, 2016

Nasdaq Stockholm AB has approved Acarix AB (publ) as issuer of shares on Nasdaq First North Premier. First day of trading will commence on December 19, 2016.

Acarix AB (publ) ("Acarix" or the "Company") has today been approved by Nasdaq Stockholm AB as issuer of shares on Nasdaq First North Premier ("Nasdaq First North Premier") in Stockholm. The first day of trading will commence on December 19, 2016.

Acarix is a Swedish/Danish commercial stage medical device company, specialised in non-invasive, non-radiative acoustic rule-out of Coronary Artery Disease (CAD). Prior to the first day of trading on Nasdaq First North Premier, the company raised SEK 140 million before transaction costs in a well-oversubscribed share issue, which added around 1,200 new shareholders to the Company's register.


Trading Information
Short name (ticker) on Nasdaq First North Premier: ACARIX
ISIN-code: SE0009268717

Advisors
Vator Securities is the financial advisor and Baker McKenzie is the legal advisor to the Company in connection with the initial public offering on Nasdaq First North Premier. Wildeco is the Certified Advisor to the Company.

For more information, please contact:
Søren Rysholt Christiansen, CEO, Acarix
E-mail: [e-mail]
Phone: [phone]

 

 

Notes to editors:

Acarix , CADScor®System and cardiac sound measurement
Acarix was established in 2009 as a spinout company from Coloplast A/S. Since 2010 key investors Seed Capital (DK) and Sunstone Life Science Ventures (DK) have financed the development of the company and supported it towards market introduction. While some founders remain in the company, Acarix has attracted a highly experienced management team who have held senior positions in international medical device companies - CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.

Acarix' CADScor^®System is based on pioneering research at Aalborg University. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.